Skip to content
value.today

Phylos Bioscience, Inc.

Total raised
$27 M
6 rounds on record
Latest round
$2 M
Oct 2024
First round on record
Aug 2015
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Phylos Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2024$2 MNo. 6Under $2 million

Phylos Bioscience, Inc.: Raise no. 6, Oct 2024

Investors in this round

8 investors had bought by the notice of Nov 1, 2024: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $4 M offered; $2 M still to sell
Smallest investment taken
$100,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Oregon

People named in the notice

  • Barbara J Peachey · Executive Officer
  • Nishan Karassik · Executive Officer, Director
  • Ralph J Risch · Executive Officer, Director
  • David J Patterson · Director
  • Mina Mishrikey · Director
  • Timothy J Gregory · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds may be used to pay normal executive compensation, the amount of which cannot be estimated at this time.”

Signed by Barbara Peachey, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 1, 2024. Read the notice at the SEC.

equitySEC
Apr 2021$3 MNo. 5$2 to $10 million

Phylos Bioscience, Inc.: Raise no. 5, Apr 2021

Investors in this round

4 investors had bought by the notice of May 5, 2021: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $3 M still to sell
Smallest investment taken
$100,000
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Oregon

People named in the notice

  • Dylan J Anderson · Executive Officer
  • Nishan Karassik · Executive Officer, Director
  • Ralph J Risch · Executive Officer, Director
  • David J Patterson · Director
  • Timothy J Gregory · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds may be used to pay normal executive compensation, the amount of which cannot be estimated at this time.”

Signed by Dylan Anderson, Chief Financial Officer. Source: SEC Form D, newest notice filed May 5, 2021. Read the notice at the SEC.

equity, debt, optionsSEC
Mar 2020$5 MNo. 4$2 to $10 million

Phylos Bioscience, Inc.: Raise no. 4, Mar 2020

Investors in this round

33 investors had bought by the notice of Jan 27, 2021: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $25 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Oregon

People named in the notice

  • Nishan Karassik · Executive Officer, Director
  • Ralph J Risch · Executive Officer, Director
  • Scott J Bowman · Executive Officer
  • David J Patterson · Director
  • Timothy J Gregory · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds may be used to pay normal executive compensation, the amount of which cannot be estimated at this time.”

Signed by Scott Bowman, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 27, 2021. Read the notice at the SEC.

equity, debtSEC
Jan 2020$5 MNo. 3$2 to $10 million

Phylos Bioscience, Inc.: Raise no. 3, Jan 2020

Investors in this round

25 investors had bought by the notice of Jan 23, 2025: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Oregon

People named in the notice

  • Barbara J Peachey · Executive Officer
  • Nishan Karassik · Executive Officer, Director
  • Ralph J Risch · Executive Officer, Director
  • David J Patterson · Director
  • Mina J Mishrikey · Director
  • Timothy J Gregory · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds may be used to pay normal executive compensation, the amount o which cannot be estimated at this time.”

Signed by Barbara A. Peachey, Vice President, Finance. Source: SEC Form D and 2 amendments, newest notice filed Jan 23, 2025. Read the notice at the SEC.

equitySEC
Apr 2019$12 MNo. 2$10 to $50 million

Phylos Bioscience, Inc.: Raise no. 2, Apr 2019

Investors in this round

33 investors had bought by the notice of Apr 19, 2021: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $26 M offered; $14 M still to sell
Smallest investment taken
$20,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Oregon

People named in the notice

  • Dylan J Anderson · Executive Officer
  • Nishan Karassik · Executive Officer, Director
  • Ralph J Risch · Executive Officer, Director
  • David J Patterson · Director
  • Timothy J Gregory · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds may be used to pay normal executive compensation, the amount of which cannot be estimated at this time.”

Signed by Dylan Anderson, Chief Financial Officer. Source: SEC Form D and 2 amendments, newest notice filed Apr 19, 2021. Read the notice at the SEC.

equity, optionsSEC
Aug 2015$1 MNo. 1Under $2 million

Phylos Bioscience, Inc.: Raise no. 1, Aug 2015

Investors in this round

7 investors had bought by the notice of Sep 16, 2016: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $6 M offered; $4 M still to sell
Smallest investment taken
$50,000
What was sold
equity, debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Oregon

People named in the notice

  • Mowgli Holmes · Executive Officer, Director
  • Nishan Karassik · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds may be used to pay normal executive compensation, the amount of which cannot be estimated at this time.”

Signed by Nishan Karassik, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 16, 2016. Read the notice at the SEC.

equity, debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Phylos Bioscience, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2025).

    SEC Form D · Jan 2025

  • The industry group it chose in its notices: Other.

    SEC Form D · Nov 2024

That is all the official record says: Phylos Bioscience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Phylos Bioscience, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 33 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Phylos Bioscience, Inc.
NameRoleNamed in
Barbara J PeacheyExecutive officerJan 2025
Nishan KarassikExecutive officerJan 2025
Ralph J RischExecutive officerJan 2025
Dylan J AndersonExecutive officerMay 2021
Scott J BowmanExecutive officerJan 2021
Mowgli HolmesExecutive officerMay 2020
David J PattersonDirectorJan 2025
Mina J MishrikeyDirectorJan 2025
Nishan KarassikDirectorJan 2025
Ralph J RischDirectorJan 2025
Timothy J GregoryDirectorJan 2025
Mina MishrikeyDirectorNov 2024
Lada J Rasochova, PhDDirectorMay 2020
Mowgli HolmesDirectorMay 2020